Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1–3 Data on of failure patients using first-generation DAAs limited.4–7 Recently, a second-generation protease- NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for failure.8 However, this other regimens not available in many resource-limited countries or reimbursed by regular insurance, recommendations regarding the selection very important. This study aimed to analyze who were re-treated with combination therapy.